FBLG · Insider Trading
FibroBiologics, Inc. Common Stock
Every open-market purchase and sale reported by FBLG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Hamid Khoja | Chief Scientific Officer | A | +298,508 | +$500.00K |
| 2026-06-23 | Matthew Link | Director | A | +30,803 deriv. | — |
| 2026-06-23 | Victoria Ninon Olivia Niklas | Director | A | +30,803 deriv. | — |
| 2026-06-23 | Robert E. Hoffman | Director | A | +30,803 deriv. | — |
| 2026-06-23 | Richard C. Cilento Jr. | Director | A | +30,803 deriv. | — |
| 2026-05-04 | Pete O'Heeron | CHIEF EXECUTIVE OFFICER | A | +92,410 deriv. | — |
| 2026-05-04 | Jason Davis | Chief Financial Officer | A | +61,607 deriv. | — |
| 2026-05-04 | Ruben A Garcia | General Counsel | A | +61,607 deriv. | — |
| 2026-05-04 | Hamid Khoja | Chief Scientific Officer | A | +61,607 deriv. | — |
| 2026-03-05 | Hamid Khoja | Chief Scientific Officer | Buy | +30,000 | +$11.40K |
| 2026-03-04 | Pete O'Heeron | CHIEF EXECUTIVE OFFICER | Buy | +51,500 | +$19.53K |
| 2026-03-03 | Jason Davis | Chief Financial Officer | Buy | +70,000 | +$28.97K |
| 2026-03-02 | Ruben A Garcia | General Counsel | Buy | +40,000 | +$13.06K |
| 2025-12-12 | Ruben A Garcia | General Counsel | Buy | +140,000 | +$47.60K |
| 2025-06-12 | Stacy Ann Coen | Director | A | +22,000 deriv. | — |
| 2025-06-12 | Richard C. Cilento Jr. | Director | A | +22,000 deriv. | — |
| 2025-06-12 | Matthew Link | Director | A | +22,000 deriv. | — |
| 2025-06-12 | Victoria Ninon Olivia Niklas | Director | A | +22,000 deriv. | — |
| 2025-06-12 | Robert E. Hoffman | Director | A | +22,000 deriv. | — |
| 2025-06-10 | Jason Davis | Chief Financial Officer | A | +450,000 deriv. | — |
| 2025-05-27 | Hamid Khoja | Chief Scientific Officer | Buy | +20,000 | +$16.80K |
| 2025-03-28 | Ruben A Garcia | General Counsel | A | +189,000 deriv. | — |
| 2025-03-28 | Pete O'Heeron | CHIEF EXECUTIVE OFFICER | A | +453,000 deriv. | — |
| 2025-03-28 | Hamid Khoja | CHIEF SCIENTIFIC OFFICER | A | +189,000 deriv. | — |
| 2024-12-30 | Ruben A Garcia | General Counsel | A | +176,200 deriv. | — |
| 2024-12-30 | Pete O'Heeron | Chief Executive Officer | A | +406,339 deriv. | — |
| 2024-12-30 | Hamid Khoja | CHIEF SCIENTIFIC OFFICER | A | +176,200 deriv. | — |
| 2024-12-09 | Pete O'Heeron | Chief Executive Officer | G | −100,000 | — |
| 2024-12-05 | Pete O'Heeron | Chief Executive Officer | G | −50,000 | — |
| 2024-08-27 | Matthew Link | Director | A | +5,000 deriv. | — |
| 2024-08-27 | Richard C. Cilento Jr. | Director | A | +5,000 deriv. | — |
| 2024-08-27 | Stacy Ann Coen | Director | A | +5,000 deriv. | — |
| 2024-08-27 | Victoria Ninon Olivia Niklas | Director | A | +5,000 deriv. | — |
| 2024-08-27 | Robert E. Hoffman | Director | A | +5,000 deriv. | — |
| 2024-08-12 | Hamid Khoja | Chief Scientific Officer | Buy | +10,000 | +$19.00K |
| 2024-08-12 | Pete O'Heeron | Chief Executive Officer | Buy | +8,500 | +$16.27K |
| 2024-03-08 | Ruben A Garcia | General Counsel | A | +180,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Hamid Khoja | Chief Scientific Officer | 301,571 | $283.45K |
| Pete O'Heeron | CHIEF EXECUTIVE OFFICER | 297,907 | $280.00K |
| Ruben A Garcia | General Counsel | 9,000 | $8.46K |
| Jason Davis | Chief Financial Officer | 3,500 | $3.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FBLG quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.